ABBOTT LABORATORIES (ABT) Overview
Healthcare • NYSE • CIK 0000001800
Loading...
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Market Cap
$185.79B
P/E (TTM)
39.5x
Rev Growth (TTM)
+10.0%
Net Margin (TTM)
9.7%
FCF Yield (TTM)
3.6%
FCF Margin (TTM)
14.0%
Figures as of September 30, 2026
Filings
Primary-source SEC disclosures, read end-to-end. SEC figures cite the filing they come from.
10-Q2026 Q32026-11-04source
8-KOct 20262026-10-21source
8-KEarnings2026-10-21source
8-KAug 20262026-08-20source
10-Q2026 Q22026-07-28source
What your agent reads
Investor Relations
Company-published material — management’s own words, not SEC-audited. Each source below is labeled so your agent knows what to verify.
IR decks — not catalogued
Company-published, not SEC-audited
Earnings
Q3
26 days ago
8-K releaseRevenue
$13.01B
+14.5%
Net Income
$920.00M
-44.0%
EPS
$0.53
-43.6%
Most recent quarterly earnings snapshot
Cash Flow Health
Free Cash Flow8/8 positive
TTM$6.8B
Q3 '26
$1.2B-39%
Q2 '26
$2.0B+117%
FCF Margin
TTM14.0%
Q3 '269.4%-41%
Sector: 3.3%Top 25%
OCF Margin
18.4%
OCF/NI1.88x
CapEx Coverage
4.2x
FCF Yield3.6%
FCF Growth (3Y)+15%
Cash Conversion Cycle
–
DSO: 63+DIO: 122−DPO: –
Cash flow trends & capital efficiency
Capital Allocation
Total Shareholder YieldTTM
TTM3.2%
Div Yield2.4%
+Buyback (TTM)0.8%
Dividend & Payout Metrics
Dividend Yield (TTM)2.4%
FCF Payout Ratio64.7%
Free Cash Flow (TTM)$6.8B
Stock Repurchases (TTM)$1.5B
Capital Return / FCF87.7%
Shares Outstanding (YoY)-0.4%↓ Buyback
Est. Dividends Paid (TTM)$4.4B
Shows how management rewards shareholders
Valuation Metrics
Price-to-EarningsTTM
39.5x
Volatile
8Q: 38.5x+2572%
Multiple expansion without fundamental improvement
High PEG ratio (4.0x) suggests expensive for growth
Valuation Lenses
Earnings
39.5x
vs – sector
Cash Flow
31.5x
EV/FCF vs –
Growth-Adj
4.0xPEG
Expensive for growth
Quality-Adj
6.4P/E per %ROIC
ROIC: 6.2%
Shareholder Returns
Dividend
2.4%
Buyback
0.8%
Total Yield
3.2%
Market Cap$185.79B
EV$212.65B
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Multi-angle valuation analysis with sector context
Margins & Efficiency
ROIC 73rd pctile
Profitability Cascade
Gross
56.9%
Operating
13.8%
Top 25% in sector
Net
9.7%
Margins Unknown
Return on Invested CapitalTTM
6.2%
Stable
-0.1% YoY8Q: 8.9%-9.4%
P25MedianP75
73rd pctl (med: -8.0%)
DuPont BreakdownROIC = Margin × Turn × (1+D/E)
NOPAT Margin
9.9%
8Q: 12.9%
Asset Turnover
0.48x
8Q: 0.52x
Leverage (1+D/E)
1.61x
D/E: 0.61x
DuPont: 7.6% ≈ 6.2% ROIC
Asset & CapEx Efficiency
Fixed Asset Turn
3.92x
8Q:3.98x
-5.4%
Invested Cap Turn
0.75x
8Q:0.84x
-17.0%
CapEx Intensity
3.2%
8Q:3.8%
CapEx/Depreciation
0.54x
FCF vs Net Margin Gap+4.3 pts
Margin trends, ROIC, and capital efficiency
Balance Sheet & Solvency
ND/EBITDA 1.8x
Net Debt / EBITDA
1.8xNet Debt: $26.86B
Interest Coverage
6.7x
+Strong interest coverage: 6.7x
Leverage Metrics
Debt-to-Equity
0.61x
Balance sheet risk & solvency analysis
Related Research
3 related posts